Loading
KL-A167 is an experimental investigational agent whose form is not stated in the registry from Sichuan Kelun-Biotech Biopharmaceutical in phase 3 trials for nasopharyngeal carcinoma and non-small-cell lung cancer, with its target not yet stated publicly.
KL-A167 is an investigational agent whose form is not stated in the registry developed by Sichuan Kelun-Biotech Biopharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: KL-A167 4-6 cycles for combined therapy.KL-A167 maintenance. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05294172 (KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma), in nasopharyngeal carcinoma and non-small-cell lung cancer. The largest, NCT05294172, plans to enrol 295 participants (actual) with primary completion expected 2027-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.KL-A167 binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"KL-A167" OR ABSTRACT:"KL-A167") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KL-A167, not a curated reading list.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma and the tag pipeline.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma and the tag pipeline.
Shares Sichuan Kelun-Biotech, Non-small-cell lung cancer and the tag pipeline.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.